The gap in your standard blood test

Your cholesterol comes back within range. Triglycerides: fine. The letter says everything is normal. And yet the fatigue lingers, recovery feels slower than it should, and something in the background hums with a low-grade inflammation you cannot quite name.

What the form almost certainly did not include was your Omega-3 Index — and that absence matters more than most people realise.

The Omega-3 Index (O3I) measures EPA and DHA — the two marine-form omega-3 fatty acids — as a percentage of total fatty acids in red blood cell membranes. Standard NHS lipid profiles, and most private panels, do not test for it. What they capture instead is the cholesterol and triglyceride content of plasma: useful, but silent on cellular omega-3 status. Plasma fatty acid levels also fluctuate with recent meals, making them an unreliable snapshot of what is actually built into your tissues.

The red blood cell membrane measurement sidesteps that problem neatly. Because red blood cells circulate for roughly 120 days before being replaced, the O3I reflects a rolling three-month average of omega-3 incorporation — a structural picture of your cellular environment, not a postprandial blip. Think of it as a stable tissue-level readout rather than a moment-in-time measure.

In Regeneration by Design, Professor Paul Lee frames Chemistry as one of the four foundational pillars of healthy ageing — the pillar governing nutrition, inflammation, and the body's internal signalling environment. The O3I sits squarely within it: not a niche supplement metric, but a window into how well your cells are equipped to manage inflammation and support repair.

The three zones — and where most Western adults land

Dr William Harris's 2008 paper in Preventive Medicine gave the O3I a clinical framework built around three zones: a high-risk band at or below 4%, an intermediate band between 4% and 8%, and a cardioprotective zone at 8% or above. The desirable target sits between 8% and 12%, a range associated in observational literature with better outcomes across heart, brain, eye, and joint health. Moving from ≤4% to ≥8% is linked — in the same body of research — with a 30–50% reduction in fatal cardiovascular events. That is an association from epidemiological data, not a guaranteed outcome, but it is a large and consistently replicated signal.

The uncomfortable part is where most Western adults actually land. UK population data places the typical adult somewhere around 4–5%. A US study puts the median at just 3.7% — the 50th percentile sitting inside the high-risk zone. The majority of people who have never tested their O3I are almost certainly somewhere between the intermediate and high-risk categories, unaware of a gap the data make plainly visible.

The point is not alarm — it is orientation. These numbers are not fixed in biology; they are a product of diet and lifestyle, and they respond to both. That is precisely what makes the O3I worth measuring.

What a low O3I does to inflammation and cell structure

Behind those risk zones lies a specific biological story. EPA and DHA, once incorporated into cell membranes, serve as precursors to anti-inflammatory molecules called resolvins and protectins. When membranes are EPA/DHA-poor, that resolution pathway weakens, and the balance tips towards pro-inflammatory signalling that can persist as a low-grade background state rather than the purposeful, acute response inflammation is designed to be.

The clinical markers reflect this directly. A 2025 study by Fan and colleagues found that higher omega-3 blood levels were significantly associated with reductions in both C-reactive protein (CRP) and the neutrophil-to-lymphocyte ratio (NLR) — two markers that readers with detailed blood work may already recognise — alongside favourable shifts in immune cell distribution. Harris, writing in 2008, made the structural argument explicit: a low O3I meets the criteria for a novel cardiovascular risk factor in its own right, one that complements rather than duplicates hs-CRP rather than replacing it in any assessment.

The structural dimension goes further still. McBurney's 2022 analysis found that an O3I above 5.6% may be needed to maintain normal red blood cell membrane integrity in healthy adults. Below that threshold, the physical architecture of the cell is affected — and it is through the membrane that nutrients enter, signals travel, and metabolic waste exits. This makes omega-3 status a matter of engineering as much as chemistry.

Diet compounds the problem. Western diets heavy in corn and soybean seed oils commonly push the omega-6 to omega-3 ratio above 15:1, far outside the 3:1–5:1 range considered healthy. Because both fatty acid families compete for the same membrane incorporation pathways, an excess of omega-6 actively limits how much EPA and DHA can be built into cell walls.

This is precisely the terrain the Chemistry pillar covers — the body's internal environment, where membrane health underpins the cellular communication and inflammatory balance that recovery, resilience, and longer-term function all depend upon.

Why the brain watches your omega-3 status too

The cardiovascular case for monitoring the O3I is well established, but the brain has its own reasons for paying attention to omega-3 status — and they are structural ones.

DHA accounts for roughly 40% of polyunsaturated fatty acids in brain grey matter. It sits within neuronal membranes, where it governs fluidity and the speed of signal transmission across synapses — the physical substrate of learning and memory. When EPA and DHA levels fall short, membranes stiffen, synaptic dynamics slow, and the downstream chemistry shifts accordingly. DHA also metabolises into neuroprotectin D1, a signalling mediator that suppresses neuroinflammation and defends neurons against oxidative stress — the kind of low-grade, chronic background inflammation that section three identified in peripheral tissues.

The O3I therefore functions as a reasonable proxy for brain-supportive omega-3 status, not solely a cardiovascular marker. Whether raising it measurably improves cognitive outcomes in healthy adults is a question the research is still working to answer; the direct evidence from supplementation trials is promising but not yet settled. The mechanistic case, however, is solid and specific — and that is what makes it worth tracking.

This is where Chemistry and Biology become genuinely inseparable in the Regeneration by Design framework: membrane composition shapes the nervous system's environment, and the nervous system shapes everything else.

Practical levers for moving your O3I

Raising the O3I begins at the dinner table. Oily fish — salmon, mackerel, sardines, and anchovies — eaten two to three times a week provides EPA and DHA in the form the body can use directly, without any conversion step. For those who cannot reach that frequency consistently, a high-quality fish oil or algal oil supplement (algal oil being the plant-derived option that still delivers preformed DHA and EPA) closes the gap; take it with a fat-containing meal to maximise absorption.

One assumption worth challenging: plant sources such as flaxseed and walnuts do contain omega-3 in the form of ALA, but the human body converts ALA to EPA and DHA poorly — typically only a few per cent of intake. For anyone relying on ALA alone to move their O3I, the shortfall is likely to persist regardless of how much flaxseed is added to porridge.

Reducing competing omega-6 seed oils — corn, soybean, and similar — is a complementary lever. The mechanism was covered in the previous section; the practical point is that cutting back on processed and fried foods heavy in these oils creates more membrane space for EPA and DHA to occupy.

A brief note on dose: some recent research has flagged a possible association between very high-dose fish oil supplementation and atrial fibrillation risk, particularly in people without pre-existing cardiovascular disease. The signal appears most relevant above pharmacological doses rather than at the 1,000–3,000 mg EPA/DHA range recommended here, but it is a reason to stay within evidenced amounts rather than assuming more is always better, and to discuss supplementation with a healthcare professional if there is any cardiac history.

Finally, Superko's 2014 analysis documented wide individual variation in O3I response to identical supplement doses — the same daily gram of EPA/DHA pushes one person into the protective zone and barely moves another. That finding reframes supplementation from a box-ticking exercise into a starting point. Knowing your current index, acting on it, and re-testing after three to four months is the only way to confirm the intervention is actually working.

Testing, monitoring, and making this part of your health design

Three to four months is the right interval between a dietary or supplementation change and a meaningful re-test — long enough for the full red blood cell turnover cycle to register the shift. Testing earlier is not wrong, but the result will be partial.

At-home fingerprick tests for the O3I are available in the UK, involving a dried blood spot sent to a laboratory. This is not something standard NHS lipid panels include, so it requires a deliberate step — but a simple one.

The structure this creates mirrors the monitoring loop many readers will recognise from glucose management: a baseline reading, a deliberate intervention, a timed re-test. The O3I is not a one-time curiosity; it is a repeating data point in a cycle of action and verification. Most people have accepted HbA1c monitoring as routine; the O3I operates on exactly the same principle, applied to a different facet of cellular chemistry.

What makes periodic re-testing more than a formality is the documented variation in individual response to supplementation. Identical daily doses of EPA and DHA produce markedly different O3I outcomes between people — the central finding of Superko's 2014 analysis. No fixed protocol can be assumed sufficient without confirmation. Re-testing converts a well-intentioned habit into verified knowledge, and if the number has not moved, the intervention can be adjusted rather than continued blindly.

For anyone managing cardiovascular conditions or taking medication that may interact with omega-3 supplementation, discussing the plan with a GP before making changes is sensible. That caveat aside, the path is straightforward for most readers.

In Regeneration by Design, Professor Paul Lee argues that health is actively designed, not passively accumulated — and that designing it requires measurement. The O3I is a Chemistry-pillar expression of that principle in its most literal form: a single number that reveals the composition of every red blood cell membrane in the body right now. Start with that number, act on it, and test again in four months. The design begins with the data.

1. [1] Omega-3 fatty acid (Wikipedia). https://en.wikipedia.org/?curid=22594 https://en.wikipedia.org/?curid=22594